TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
about
The epigenetic landscape of acute myeloid leukemiaImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FGenetics of myeloproliferative neoplasmsEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementMechanisms of epigenetic regulation of leukemia onset and progressionThe TET2 interactors and their links to hematological malignanciesLoss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosisNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Epigenetics in Cancer: A Hematological PerspectiveCalreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferationDeletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignanciesHigh accuracy mutation detection in leukemia on a selected panel of cancer genesThe behaviour of 5-hydroxymethylcytosine in bisulfite sequencingRefined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Immunomodulatory agents in myelofibrosis.Efficacy of ruxolitinib for myelofibrosis.Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.5-Hydroxymethylcytosine promotes proliferation of human uterine leiomyoma: a biological link to a new epigenetic modification in benign tumors.Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failureThe C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.Pathogenic microRNA's in myeloid malignancies.IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
P2860
Q21284742-8F79959D-2070-439E-955E-53A177D9085AQ24306181-AD29EBA9-62FA-4EDB-B27D-07740C72FC41Q26738514-A55A9960-0076-4982-9C7D-15402A6CDCEAQ26777265-3ABF08F4-5CB4-4E7F-992B-82691DC3DEBEQ26795666-4D17BBE5-B683-46BA-874A-356CEF2F91CCQ26823651-995BD9BC-F053-4634-8692-074801E3D0C1Q26828777-CBA3B931-CF57-4D09-B5F1-57FB4EDE7C96Q26851894-C8065FDB-B019-4941-BDF0-7C1AF36D6573Q26861785-38AAA2FA-4516-4E38-8E36-7C98DB6B8A9DQ27002485-F409529C-4781-4AC4-BC6F-61175CD73106Q27334940-442D099F-8199-44AF-981B-6DBE9A963FD1Q27687464-5C5BED09-90F3-4E62-AEA5-A4216FB18B42Q27851621-0B8BF094-41AB-41A8-9BF7-D28559457917Q27853179-B762661E-4289-439B-99CC-966F70855270Q28077082-7857D874-83ED-4528-9551-214E6E22D59EQ28084727-E3008EE1-87B9-46B7-A77D-A44418CBD1C3Q28255707-5733C3A0-36A0-45E8-9AFB-E8E966A79A8DQ28591763-B124ACB6-46B4-4587-AC5A-087570FB581CQ28728910-5AC134A2-91AE-45E7-97B7-331FEA26B817Q28749183-05D9ABEB-30E8-4227-A544-795547325330Q33392291-F34F81A4-EC4B-4F7E-854C-D50F26B8BA3FQ33398180-9DFA7322-EE66-4003-8532-4CE222C7D384Q33401615-A2B51091-FB45-44D6-AC6B-288E303E2517Q33415489-A5BD5CCD-9FFA-4C9C-A9D8-B59A11F79BD3Q33420358-E90B8363-A6E7-4A50-B67D-84C84A299630Q33517074-B2EC9108-EC2E-4A2E-8D78-FC09F91EC143Q33570198-557DA7F4-C6DF-411E-8080-12319742A6D0Q33583033-2BD0C0EA-4D09-4F1E-8719-4CC2CCDD66DCQ33620407-85137186-68BB-4B69-939C-5FE748267F6BQ33629603-FB9F5DE2-7AF2-4699-A223-E50E433BFD3DQ33829778-82F67056-2D55-4C44-AF0E-C03247EADBFEQ34129617-460DB4DC-A341-4AE7-8454-4F7346E9BE5DQ34301317-E8EC8DC8-74F1-4C0A-82C4-492CB9EE43D5Q34302770-63678380-3848-4C8D-89DB-1FE173A881C0Q34348505-9D66837F-0F78-4298-8BA8-F29C2345CA14Q34467863-44B4A3B4-EA4C-48E1-B542-88502BF93BEDQ34541057-D256F6E3-BEC7-4EDB-9078-764D363C3688Q34562170-232A3D44-3D1A-498C-AA07-3A76918F5515Q34629928-465E3A74-DA55-4698-B3B6-F2AC87ADC33CQ34876785-643C91CD-06C9-4A3A-AFAE-13A8A86F99A9
P2860
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@ast
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@en
type
label
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@ast
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@en
prefLabel
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@ast
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@en
P2093
P2860
P356
P1433
P1476
TET2 mutations and their clini ...... ombocythemia and myelofibrosis
@en
P2093
A Mullally
A Pardanani
C A Hanson
D G Gilliland
F Delhommeau
P2860
P2888
P304
P356
10.1038/LEU.2009.47
P577
2009-03-05T00:00:00Z